title: Leukocytoclastic vasculitis during pegylated interferon and ribavirin treatment of hepatitis C virus infection.
authors.forename: Esra
authors.initials: E
authors.lastname: Adişen
authors.forename: Murat
authors.initials: M
authors.lastname: Dizbay
authors.forename: Kenan
authors.initials: K
authors.lastname: Hizel
authors.forename: Nilsel
authors.initials: N
authors.lastname: Ilter
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects*; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000139:chemically induced*
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a